BeiGene Showcases Promising Waldenström’s Macroglobulinemia Research at IWWM 2024 San Mateo, Calif. – BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology leader, announced its participation in the…
Alnylam Submits Type II Variation to EMA for Vutrisiran in ATTR Amyloidosis with Cardiomyopathy CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 16, 2024—Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced the submission of a Type II…
Sanofi and Orano Partner to Develop Next-Generation Radioligand Therapies Paris, October 17, 2024 – Sanofi and Orano Med, a subsidiary of the Orano Group and a leader in targeted alpha…
AstraZeneca Showcases Key Advances in Respiratory Infection Protection at IDWeek 2024 AstraZeneca is set to present significant new findings on the protection against serious respiratory infections caused by respiratory syncytial…
Etcembly and University of Surrey Launch Study to Transform Cancer Treatment British techbio innovator Etcembly is collaborating with researchers from the University of Surrey to launch a groundbreaking study aimed…
STRIDE-8 Study Results Highlight CAPVAXIVE’s Efficacy in Pneumococcal Disease Prevention CAPVAXIVE Demonstrates Strong Immune Response and Coverage Against Major Serotypes RAHWAY, N.J. — Merck (NYSE: MRK), known as MSD outside…
ViiV Healthcare Presents Real-World Evidence for Apretude (Cabotegravir Long-Acting) at IDWeek 2024 GSK plc (LSE/NYSE: GSK) has announced that ViiV Healthcare, a global leader in HIV treatment and prevention, has…
GSK’s Gepotidacin Accepted for FDA Priority Review to Treat Uncomplicated UTIs GSK plc (LSE/NYSE: GSK) has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug…
Bayer to Present Latest Research on Menopausal Sleep Disturbances at IMS 2024 Bayer is set to showcase its latest research on menopause symptoms, particularly sleep disturbances, at the 19th World…
The Women’s Brain Foundation and Medscape Education Launch Learning Center on Sex and Gender in Brain Health The Women’s Brain Foundation (WBF), a leader in integrating sex- and gender-based research…
Sensorion to Present GJB2-GT Research at ESGCT Congress 2024 Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of innovative therapies for hearing loss, has announced…
GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024 GenSight Biologics (Euronext: SIGHT), a biopharmaceutical company specializing in innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders,…